Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 26

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 26
---
 Meeting.

On March 20, 2025, Mr. Thompson contacted Mr. DeBoom by telephone to coordinate a follow-up meeting. That same day, Mr. DeBoom emailed Mr. Thompson and a representative of Latham & Watkins LLP to schedule a teleconference. Mr. Thompson responded via email that same day and arranged for a March 21, 2025 teleconference meeting.

On March 21, 2025, Mr. McFarlane, Mr. Thompson, and a representative of Latham & Watkins LLP met with Mr. DeBoom, Mr. Mangless, and Dr. Mickle via teleconference to discuss the Board’s rejection of the Mangless Offer. Following the meeting, Mr. DeBoom contacted Mr. Thompson via telephone and proposed that in exchange for Mr. Mangless’ agreement to withdraw the Mangless Nomination, the Board would nominate and support Dr. Mickle as well as one additional qualified candidate selected by the Board, in each case to stand for election to the Board at the Annual Meeting. Mr. DeBoom expressed that Mr. Mangless would support the Board’s qualified nominee, including either of Ms. Favorito or Wendy Dixon, Ph.D. (the two incumbent directors whose terms were set to expire at the Annual Meeting and who are nominated by the Board for re-election at the Annual Meeting), provided that the Board also supports Dr. Mickle (the “Updated Mangless Offer”). Following discussion, the Board voted not to accept the Updated Mangless Offer and not to agree to nominate Dr. Mickle for election to the Board at the Annual Meeting

On March 21, 2025, Mr. DeBoom sent an email to Mr. Thompson, copying a representative of Latham & Watkins LLP, to reiterate the Updated Mangless Offer.

On March 24, 2025, the Board held a meeting to discuss the Mangless Nomination, Mangless Offer, and Updated Mangless Offer. Following discussion, the Board voted to decline both the Mangless Offer and the Updated Mangless Offer and proceed with the nomination of Wendy Dixon, Ph.D. and Tamara Favorito as its Class I director nominees for the Annual Meeting.

On March 24, 2025, Mr. Thompson sent an email to Mr. DeBoom, copying a representative of Latham & Watkins LLP, providing Mr. Mangless with the required notification of the Company’s nominees for election at the Annual Meeting, Ms. Favorito and Dr. Dixon, pursuant to Rule 14a-19